SUPPORT FOR CANADIAN CENTER

12 April 1992

One of the problems that Canada's pharmaceutical industry has is that it is dominated by foreign companies which do not carry out R&D in the country, according to Colin Mallet, chairman of the Institute for Research in Industrial Pharmacy.

But now, the institute has received C.$6 million ($5 million) from federal and Quebec governments to build laboratories and offices over the next year, according to local reports. Drug researchers throughout Canada are said to be in support of the new pharmaceutical research center, which will be built in the Montreal area.

Mr Mallet, who is also president of Sandoz Canada, commented that until now this kind of work has been carried out at university faculties of pharmacy, without a national center to coordinate work by academics.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight